Search
Trimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigationalTrimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. … [A233215] The increased intracellular calcium decreases contractility.
Clofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalUnlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnIf so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalIt has been suggested that the dual activity of ritlecitinib toward JAK3 and the TEC kinase family block cytokine signaling as well as the cytolytic activity of T cells, both implicated in the pathogenesis … [A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family.
Copper oxodotreotide Cu-64
go.drugbank.com/drugs/DB15873Approved[A220348] Further studies should be performed to compare the two tracers. … [A220348] In a head-to-head trial, the former tracer detected twice as many lesions as the latter.[A220348]
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other … being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.
Ramelteon
go.drugbank.com/drugs/DB00980ApprovedInvestigationalRamelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). … Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Categories: Melatonin Receptor AgonistsSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigationalreferred to as "cold agglutinin". … In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment.
Metreleptin
go.drugbank.com/drugs/DB09046ApprovedInvestigational[L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized … Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy.